Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker

Keeping Track Feature image

The first two weeks of 2021 have been quiet on the US FDA drug approval front, but the annual (albeit virtual) J.P. Morgan conference once again ensured a steady flow of sponsor news.

The approvals concentrated in oncology, including new breakthrough therapy designated-indications for Enhertu and Xalkori, while the submissions ranged from primary...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers